The purpose was to assess the incidence and risk factors associated with symptomatic venous thromboembolism in patients undergoing below knee immobilization for non-operative foot or ankle injury. We included all foot and ankle patients between January 2005 and May 2016 who underwent non-operative management using below knee immobilization with cast, splint, brace, and/or boot. The primary outcome was the development of a venous thromboembolism within 90 days of immobilization initiation. Of 6,088 patients, twenty-three (0.38%) developed a venous thromboembolism. Risk factors for venous thromboembolism were age>50 years, unremovable immobilization, Achilles tendon rupture, Modified Charlson Comorbidity Index>2, patients on chemoprophylaxis, varicose veins, history of venous thromboembolism, known hypercoagulability disorder, and rheumatoid arthritis. Routine thromboprophylaxis after below-knee immobilization for non-operative foot or ankle injury may be beneficial in these specific subpopulations. These data can facilitate more substantive shared decision-making between providers and patients with respect to use of thromboprophylaxis. ß
Despite the widespread use of below-knee immobilization for treating non-operative foot and ankle injuries, 1 there remains no consensus regarding the need for venous thromboembolic (VTE) prophylaxis in such patients. 2 The most recent American College of Chest Physicians guidelines in fact did not recommend the routine use of VTE prophylaxis in patients with isolated lower-leg injuries requiring below-knee immobilization. This recommendation, however, was rated as "weak"-underscoring its basis in low-quality evidence-and it did not differentiate between operative and non-operative injury. 3 In contradistinction, a recent Cochrane meta-analysis alternatively concluded that patients treated non-operatively with lower-leg immobilization demonstrate a heightened risk of VTE-and recommended the routine use of chemoprophylaxis. 4 Notably, such studies demonstrated sizeable variability in VTE incidence, ranging from 0.0% to 17.3%, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] possibly stemming from variations in patient risk factors. [7] [8] [9] This high variability in VTE incidence suggests that specific subpopulations of patients who present with foot or ankle injury may be at heightened risk of VTE, and may therefore benefit from chemoprophylaxis when undergoing below-knee immobilization. It is currently unknown, though, as to which patients are at heightened risk and which are not. This paucity of data makes it difficult for the care provider to make evidence-based decisions on the use of chemoprophylaxis, which in itself is not an entirely benign treatment modality.
The aim of this study was to assess the incidence of and determine the risk factors associated with symptomatic VTE in a large cohort of patients undergoing a period of below-knee immobilization for non-operative foot or ankle injury.
METHODS

Level of evidence: Therapeutic Level III
Study Design and Participants
This retrospective study was approved by the Institutional Review Board. Eleven Current Procedural Terminology (CPT) codes, five International Classification of Diseases, ninth revision (ICD-9-CM) codes, and fourteen International Classification of Diseases, tenth revision (ICD-10-PCS) codes were used to identify patients 18 years of age or older, that were immobilized with a cast, splint, brace, and/or boot for their foot and ankle condition between January 2005 and May 2016 at three hospitals (Table S-1) (Table S-2) . Medical record data of patients with one of these CPT codes and ICD-9/10-CM codes were retrieved through our Research Patient Data Registry (RPDR). The RPDR is a centralized clinical data registry that comprises diagnostic and billing codes, demographic information (e.g., sex, date of birth, and race), clinical encounters, transfusion data, laboratory values, and operative and radiology reports. Exclusion criteria included: (i) patients younger than the age of 18; (ii) patients that underwent lower extremity surgery within 90 days prior to or within 90 days after initiation of immobilization; (iii) clinical follow-up less than 90 days; and (iv) pre-immobilization thromboembolic event on admission. Only the first period of immobilization was included when a patient underwent subsequent repeated immobilization.
Outcome Measures and Explanatory Variables
The primary outcome variable of interest was any symptomatic DVT or PE within 90 days after initiation of immobilization, as confirmed by lower extremity ultrasound or PEprotocol chest computed tomography (PE-CT). Venous thromboembolism is a systemic disease and by being immobilized the patient has a higher chance of developing DVT ipsilateral as well as contralateral. Therefore, we included ipsilateral as well as contralateral DVT from the side of injury. Patients suspected to have a DVT or PE were identified through specific and unspecific ICD-9-CM and ICD-10-CM codes (Table S-3) . A prior study found that use of these diagnosis codes for identifying VTE patients has a high true negative rate, but low true positive rate. 15 Therefore, all included patients were manually evaluated by two of the authors to assess validation of diagnosis codes against the documentation of DVT or PE. The location of deep venous thrombosis was specified as proximal (popliteal vein or proximal) or distal (all veins distal to the popliteal vein). No patients underwent routine ultrasound screening as part of their care.
We included the following explanatory variables: Sex, age, body mass index (BMI), type of immobilization, ankle fracture, Achilles tendon rupture, tobacco use, pregnancy, contraception or postmenopausal hormonal replacement therapy, Modified Charlson Comorbidity Index, 16 patients on chemoprophylaxis, and other comorbidities, specifically varicose veins, history of VTE, known hypercoagulability disorder, family history of coronary artery disease (CAD), rheumatoid arthritis, diabetes mellitus, and active cancer and/or history of cancer. Patients were considered obese when they had a BMI greater than 30 recorded in their medical record during the year of immobilization. Type of immobilization during follow-up was divided into two groups: (i) initial unremovable immobilization with cast or splint, potentially followed by either a removable boot and/or brace, and (ii) removable immobilization with a splint, brace, or boot. Tobacco use was classified as current smoker/history of smoking and no history of tobacco use. The use of oral contraceptives or hormone replacement therapy were evaluated using medication history recorded within 120 days prior to the date of immobilization. The Modified Charlson Comorbidity Index was determined through a previously described algorithm based on the ICD-9-CM codes. 17, 18 Chemoprophylaxis was recorded in the medical records within 180 days prior to immobilization, as well as during a 90-day postimmobilization follow up period-which included medication prescribed during any inpatient stay. Possible anticoagulant therapy included warfarin, low-molecular-weight heparin, factor Xa inhibitors, and direct thrombin inhibitors with or without aspirin. Patients taking aspirin, if continued during immobilization, were considered to be receiving chemoprophylaxis. Malignancy or a history of malignancy was recorded as a cancer or history of cancer.
Data Analysis
Variables were presented with frequencies and percentages for categorical variables and as means with standard deviations (SD) for continuous variables. To determine the explanatory variables associated with VTE, we used chi-squared tests for dichotomous and categorical variables, and logistic regression analysis for continuous variables. The presence of VTE after immobilization was defined as a VTE confirmed by ultrasound or PE CT within 90 days of the first day of immobilization. The days between initiation of immobilization and VTE diagnosis were recorded. The overall incidence of symptomatic DVT and PE was calculated by dividing the number of VTE patients by the total amount of patients included in this study. Bivariate analyses were performed to create 95% confidence intervals with odds ratios (ORs) for associations between explanatory variables and symptomatic VTE. All explanatory variables with a two-sided p-value less than 0.05 were considered to indicate statistical significance. p values were not adjusted for multiple testing. In light of the rarity of VTE events (n ¼ 23) and the number of predictors studied (n ¼ 19), a multivariable regression model was not developed because of concerns about the reliability of the model. Stata (Stata version 13, Statacorp LP, College Station, TX) was used for all statistical analyses.
RESULTS
Baseline Characteristics
The initial RPDR search identified 19,030 patients between January 2005 and May 2016. After applying inclusion and exclusion criteria, 6,088 patients remained for final analysis (Fig. 1 ). There were 2,476 (41%) males and 3,612 (59%) females, with a mean age of 45 AE 17 years. Five thousand three hundred thirtyeight patients (88%) did not receive chemoprophylaxis. Of the 888 patients who underwent initial unremovable immobilization, 7 (0.79%) developed VTE. Of the 5,200 patients who underwent removable immobilization, 16 (0.31%) developed VTE.
Venous Thromboembolism
Twenty-three (0.38%) patients developed a symptomatic VTE (Table 1) . Nineteen (0.31%) patients were diagnosed with a DVT and four patients developed a PE (0.07%). The average age of VTE patients was 56 AE 18 years. Fifteen (65%) of these VTE patients did not receive chemoprophylaxis. Table 2 ). In addition, five patients had a superficial venous thrombosis within our follow up period, which was not considered to be a DVT event for the purposes of this study. None of the patients that developed a PE died.
DISCUSSION
There is currently a paucity of data available to effectively guide clinicians regarding which patients, if any, might benefit from chemoprophylaxis when undergoing below knee immobilization as part of a nonoperative approach to any foot or ankle injury. In this particular patient cohort (n ¼ 6,088), we found an overall low rate of symptomatic VTE of 0.38% (0.31% DVT and 0.07% PE), which is a number that is consistent with other published articles that often dismiss the need for any VTE chemoprophylaxis based on that overall average. What distinguishes the present study, however, is the fact that patient numbers are not only much higher than most of these earlier reports but also that specific subpopulations of patients were carefully culled and analyzed for any potentially predisposing risk factors. Indeed, the most important finding in this investigation is that-despite an overall extremely low incidence of venous thromboembolic disease (VTED) following immobilization after foot or ankle injury-there are clearly some specific subpopulations of patients who remain at high risk of VTED under these circumstances that the provider should be aware of. Significant patient risk factors included age>50 years, unremovable immobilization, Achilles tendon rupture, Modified Charlson Comorbidity Index>2, patients on chemoprophylaxis, varicose veins, history of VTE, known hypercoagulability disorder, and rheumatoid arthritis. The incidence of symptomatic VTE in our study among foot and ankle patients undergoing below-knee immobilization for non-operative injury falls well within the wide range of findings from previous studies, which themselves ranged from 0.0% to 17.3%. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The largest retrospective study of which we are aware included 14,777 patients treated non-operatively for an ankle fracture and demonstrated a rate of symptomatic VTE of 0.22%. Two smaller studies involving 200 and 150 patients treated non-operatively for foot and ankle fractures found 1 (0.5%) symptomatic DVT and 3 (2%) symptomatic VTE respectively. 6, 14 A small prospective series of 100 patients treated nonoperatively for an ankle fracture found five patients with DVT, but this study was based on routine screening rather than selective ultrasound in symptomatic patients. 5 Our patient cohort had a markedly higher risk of developing VTE compared to the general population. During the 90-day follow-up, the incidence 19 Most DVT's affecting foot and ankle patients are distal to the popliteal fossa, which have a lower recurrence rate as well as a lower risk of progression to PE than more proximal DVT's. 9 In the current study, 52% of the reported VTE were distal DVT's without PE.
Certain patient populations may also be at higher risk for VTE events. Patients with acute Achilles tendon ruptures may have a heightened risk of VTE, with reported rates of DVT in the literature range from 0.4% to 34% without the use of chemoprophylaxis, 10 many of which are pre-operative even among those studies focusing on operative patients. 20 Unremovable immobilization also has been implicated in the occurrence of VTE events. A large, population-based case-control study (4,418 cases; 6,149 controls) found a 56-fold increased risk of venous thrombosis in patients with below-knee cast immobilization as compared with patients with no cast. 21 In addition, a recent prospective trial examining 1435 patients who presented to the emergency department and were treated for at least 1 week with casting of the lower leg (with or without surgery before or after casting) demonstrated an overall incidence of symptomatic VTE of 1.6% (23/1,435) . 22 Yet another large retrospective study having 2,761 patients with isolated injuries below the knee treated non-operatively demonstrated an incidence rate of 0.98% (27/2,761), 9 with the majority of patients having unremovable immobilization, 53% (n ¼ 1,489). Other risk factors may include patients with a Charlson comorbidity index greater than 1, 8 non-weight bearing status, patients over the age of 50 years, and greater injury severity. 9 Additional factors to consider may include advanced age, fractures, elevated BMI, and varicose veins. 7 Similar to our findings, coagulopathy, history of VTE, and increasing age, were found to be risk factors for symptomatic VTE in 57,619 Danish patients undergoing operative treatment distal to the knee. 23 In contrast, some factors such as use of oral contraception were associated with VTE in their study but not in ours, even though a comparable percentage of patients used oral contraception, 4.0% (2,328/57,619 patients) versus 3.9% (235/ 6,088 patients). A possible explanation for this discrepancy may be that the number of VTE events in our cohort was smaller (n ¼ 23) compared to 594 VTE events in their study. Therefore, in our study a relatively small change in the number of VTE events recorded within patient subgroups can have a disproportional large effect. Notably, none of these studies, nor our own, found diabetes mellitus to be a risk factor.
Our study demonstrated that 1% (8/750) of patients developed VTE despite anticoagulant therapy, while 0.3% (15/5,323) of patients without chemoprophylaxis developed VTE. This might be explained because chemoprophylactic therapy was used preferentially in higher risk patients, hence the "a priori" chance of developing VTE for these patients was higher-regardless of chemoprophylactic strategy used. Almost 80% of incident VTE events are attributable to known major VTE risk factors and one-third of incident idiopathic VTE events are attributable to obesity. 24 Another explanation can be that certain patients were treated subtheurapeutically, so that it did not effectively lower the VTE rate. Notably, it is unclear whether the use of chemoprophylaxis is effective in lowering the incidence of VTE events. A recent randomized trial involving 1519 patients concluded that chemoprophylaxis with LMWH during the period of immobilization in patients with casting of the lower leg was not effective for the prevention of symptomatic venous thromboembolism. 22 In contrast, several other randomized designed studies found chemoprophylaxis to be useful in conservative treated foot and ankle patients. A randomized prospective study involving 339 outpatients with plaster-cast immobilization of the leg demonstrated that the overall VTE rate was significantly reduced from 17.1% in the control group as compared to 6.1% in the prophylaxis group receiving LMWH (p < 0.05). 12 Yet another prospective randomized study with 253 patients who sustained an injury of the lower limb and were immobilized in a nonremovable plaster cast demonstrated that without prophylaxis 16.5% of patients developed a DVT as compared to 4.8% of patients receiving prophylaxis (p < 0.01). 7 Similarly, another prospective, double blind, placebo-controlled trial involving 440 patients showed that a DVT was diagnosed in 9% of the patients randomly assigned to receive reviparin and 19% of those randomly assigned to receive placebo. 13 There are a few limitations to consider. First, our study only included symptomatic VTE events, whereas studies with routine VTE screening are likely to report a higher incidence. One can argue, however, that asymptomatic VTEs are unlikely to be clinically relevant, and it makes our methods pragmatic given that routine screening is not generally employed. Second, our analysis of risk factors for VTE is not adjusted because of concerns about the reliability of a multivariable regression model due to the limited number of VTE events among our population. Third, we did not determine the incidence and risk factors associated with bleeding adverse events or immunogenic responses to heparin-based anticoagulants, both of which can be life-threatening among patients receiving chemoprophylaxis. 25, 26 This information is integral towards understanding the risks and benefits of chemoprophylactic use in patients with below-knee injuries. Fourth, patients weight baring status could not be adequately retrieved, which has been described as a potential risk factor for VTE. 9 Early weightbearing may feasibly obviate some of the risks of immobilization. Fifth, we were not able to accurately determine the duration of the immobilization period due to variability in the medical record. Lastly, our findings may influence providers to start anticoagulating all patients based on the risk factors we found. However, one must take into consideration, that the number of patients that developed a VTE was relatively low and more than half of patients developed a distal DVT. Moreover, as we mentioned earlier, there are also risks associated with anticoagulation.
In summary, while the overall incidence of VTE during a course of below knee immobilization in the non-operative management of a foot and ankle injury is low, there appear to be specific subpopulations of patients who are associated with a significantly heightened risk of symptomatic VTE. Routine thromboprophylaxis after below-knee immobilization for non-operative foot or ankle injury may be beneficial in these specific subpopulations. These data can be valuable for facilitating more substantive shared decision-making between providers and patients with respect to use of thromboprophylaxis.
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